CN114026082B - 吡啶-3-基衍生物 - Google Patents

吡啶-3-基衍生物 Download PDF

Info

Publication number
CN114026082B
CN114026082B CN202080044333.8A CN202080044333A CN114026082B CN 114026082 B CN114026082 B CN 114026082B CN 202080044333 A CN202080044333 A CN 202080044333A CN 114026082 B CN114026082 B CN 114026082B
Authority
CN
China
Prior art keywords
isopropylphenyl
chloro
methoxypyridin
azetidine
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080044333.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114026082A (zh
Inventor
马丁·博利
克莉丝汀·普罗奇
西里尔·莱斯高普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actelion Pharmaceuticals Ltd
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of CN114026082A publication Critical patent/CN114026082A/zh
Application granted granted Critical
Publication of CN114026082B publication Critical patent/CN114026082B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Debugging And Monitoring (AREA)
CN202080044333.8A 2019-06-18 2020-06-17 吡啶-3-基衍生物 Active CN114026082B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2019065963 2019-06-18
EPPCT/EP2019/065963 2019-06-18
PCT/EP2020/066767 WO2020254408A1 (en) 2019-06-18 2020-06-17 Pyridin-3-yl derivatives

Publications (2)

Publication Number Publication Date
CN114026082A CN114026082A (zh) 2022-02-08
CN114026082B true CN114026082B (zh) 2024-06-07

Family

ID=71105482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044333.8A Active CN114026082B (zh) 2019-06-18 2020-06-17 吡啶-3-基衍生物

Country Status (18)

Country Link
US (1) US12479820B2 (enExample)
EP (1) EP3986884B1 (enExample)
JP (1) JP7494222B2 (enExample)
KR (1) KR102786045B1 (enExample)
CN (1) CN114026082B (enExample)
AR (1) AR119162A1 (enExample)
AU (1) AU2020298014B2 (enExample)
BR (1) BR112021025236A2 (enExample)
CA (1) CA3143618A1 (enExample)
CL (1) CL2021003348A1 (enExample)
IL (1) IL288950B2 (enExample)
MA (1) MA56504A (enExample)
MX (1) MX2021015727A (enExample)
PH (1) PH12021553178A1 (enExample)
SG (1) SG11202111162PA (enExample)
TW (1) TWI845708B (enExample)
UA (1) UA130692C2 (enExample)
WO (1) WO2020254408A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE061559T2 (hu) 2018-06-07 2023-07-28 Idorsia Pharmaceuticals Ltd Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásuk
WO2021110805A1 (en) * 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
WO2025169931A1 (ja) * 2024-02-05 2025-08-14 Ｕｂｅ株式会社 カルボキサミド化合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088908A2 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Heterocyclo inhibitors of potassium channel function
EP2481725A1 (en) * 2009-09-25 2012-08-01 Astellas Pharma Inc. Substituted amide compound
CN105189481A (zh) * 2013-03-13 2015-12-23 艾伯维公司 吡啶cdk9激酶抑制剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130088C (enExample) 1960-03-14
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
GB9420763D0 (en) 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
AU7961300A (en) 1999-10-29 2001-05-14 Yamanouchi Pharmaceutical Co., Ltd. Kainic acid neurocytotoxicity inhibitors
AU2001262185A1 (en) 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2005037269A1 (ja) 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
CA2544981A1 (en) 2003-11-12 2005-05-26 Merck & Co., Inc. 4-phenyl piperidine sulfonyl glycine transporter inhibitors
EP1687296A1 (en) 2003-11-18 2006-08-09 Warner-Lambert Company LLC Antibacterial aminoquinazolidinedione derivatives
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
JP5164510B2 (ja) 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
AU2008311971A1 (en) 2007-10-18 2009-04-23 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
EP2297153B1 (en) 2008-04-21 2015-05-27 Lexicon Pharmaceuticals, Inc. Limk2 inhibitors, compositions comprising them, and methods of their use
AU2009243756B2 (en) 2008-05-05 2013-06-27 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
BRPI0918971A2 (pt) 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
ES2682303T3 (es) 2010-08-05 2018-09-19 Zoetis Services Llc Derivados de isoxazolina como agentes antiparasitarios
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為ｍＰＧＥＳ－１抑制物的三環化合物
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
PT2683723T (pt) 2011-03-10 2016-08-05 Zoetis Services Llc Derivados espirocíclicos de isoxazolina como agentes antiparasitários
JP2015506349A (ja) 2011-12-21 2015-03-02 アルデリックス， インコーポレイテッド 非全身性ｔｇｒ５アゴニスト
WO2014079805A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
JP2017500287A (ja) 2013-11-06 2017-01-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso
HUE061559T2 (hu) 2018-06-07 2023-07-28 Idorsia Pharmaceuticals Ltd Alkoxi-helyettesített piridinil származékok mint LAP1 receptor antagonisták és fibrózis kezelésében való alkalmazásuk
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088908A2 (en) * 2002-04-19 2003-10-30 Bristol-Myers Squibb Company Heterocyclo inhibitors of potassium channel function
EP2481725A1 (en) * 2009-09-25 2012-08-01 Astellas Pharma Inc. Substituted amide compound
CN105189481A (zh) * 2013-03-13 2015-12-23 艾伯维公司 吡啶cdk9激酶抑制剂

Also Published As

Publication number Publication date
JP7494222B2 (ja) 2024-06-03
WO2020254408A1 (en) 2020-12-24
EP3986884A1 (en) 2022-04-27
IL288950A (en) 2022-02-01
IL288950B2 (en) 2025-03-01
CN114026082A (zh) 2022-02-08
AR119162A1 (es) 2021-12-01
AU2020298014B2 (en) 2026-02-05
CA3143618A1 (en) 2020-12-24
US20220251068A1 (en) 2022-08-11
TWI845708B (zh) 2024-06-21
MA56504A (fr) 2022-04-27
CL2021003348A1 (es) 2022-09-23
KR102786045B1 (ko) 2025-03-24
JP2022537177A (ja) 2022-08-24
EP3986884B1 (en) 2026-07-08
US12479820B2 (en) 2025-11-25
BR112021025236A2 (pt) 2022-02-01
AU2020298014A1 (en) 2022-02-10
IL288950B1 (en) 2024-11-01
UA130692C2 (uk) 2026-04-22
PH12021553178A1 (en) 2022-11-07
MX2021015727A (es) 2022-01-24
KR20220020921A (ko) 2022-02-21
SG11202111162PA (en) 2021-11-29
TW202115011A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
CN112055711B (zh) 作为lpa拮抗剂的环己基酸三唑吖嗪类
JP5318867B2 (ja) ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト
RS58024B1 (sr) Biciklični heterociklični derivati kao irak4 inhibitori
JP2010526145A (ja) ［６，６］および［６，７］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
CN114761001A (zh) 氮杂环丁烷lpa1受体拮抗剂与抗纤维化药剂的组合
CN112236424B (zh) 经烷氧基取代的吡啶基衍生物
TW202045498A (zh) 作為法尼醇x受體調節劑之經取代雙環化合物
TWI845708B (zh) 吡啶-3-基衍生物
WO2025137541A1 (en) Kinase modulators and methods of use thereof
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
HK40066271B (en) Pyridin-3-yl derivatives
HK40066271A (en) Pyridin-3-yl derivatives
EA047605B1 (ru) Пиридин-3-ильные производные
EA040901B1 (ru) Алкокси-замещенные пиридинильные производные в качестве антагонистов рецепторов lpa1 и их применение для лечения фиброза
TW202409011A (zh) 人類呼吸道融合病毒及間質肺病毒抑制劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40066271

Country of ref document: HK

GR01 Patent grant